News

Considering the range of neurological symptoms normally associated with adult multiple sclerosis (including loss of coordination, weakness, fatigue, and trouble thinking), symptoms of pediatric multiple sclerosis are often nonspecific and affect the intestinal system. Intestinal mobility and sensation, vomiting, and long transit time for digestion (dysphagia) are symptoms that also…

Dr. Jose Álvarez-Cermeño and Dr. Luisa Villar from Instituto Ramón y Cajal de Investigación Sanitaria in Madrid, Spain recently published in the journal Nature Reviews Neurology a review on the work developed by Dr. An Goris and colleagues on the link between genetic factors and multiple sclerosis…

The U.S. Food and Drug Administration (FDA) has announced the approval of the first generic version of Copaxone (glatiramer acetate injection) for the treatment of relapsing forms of multiple sclerosis (MS). The administration has granted Sandoz marketing authorization for glatiramer acetate in 20 mg/1 ml…

People with multiple sclerosis (MS) commonly experience a low pain threshold and sensitivity to heat and cold. If a person has multiple sclerosis along with fibromyalgia (FM), that could make this sensitivity even more intense. Until now, no group has studied this phenomenon. In a study titled “…

The American Academy of Neurology (AAN) recently announced the results of a new study that evaluated an experimental drug for multiple sclerosis (MS) with the potential to repair damaged myelin layers, a fatty material that covers and protects neurons. These findings will be presented at the 67th AAN Annual Meeting,…

A team led by researchers at the University of British Columbia in Canada recently published results in the European Journal of Neurology showing that treatment with beta-interferon has no effect on secondary progressive multiple sclerosis (MS) disease onset. The study is entitled “Beta-interferon exposure and…

A new commentary concerning genetic variability in multiple sclerosis patients highlights a new marker of disease severity. Local IgG (antibody) synthesis is found in over 90% of multiple sclerosis patients, and there is a genetic basis for this hallmark of disease. “A new genome-wide association…

A team of Kessler Foundation researchers recently published their findings on the MEMREHAB trial, whereby treatment with the modified Story Memory Technique (mSMT) may be affected by cognitive dysfunction. The study entitled “The influence of cognitive dysfunction on benefit from learning and memory rehabilitation in MS:…

Novartis will present novel Gilenya data, demonstrating the company’s methods for assessing the impact of relapsing multiple sclerosis (RMS) in both patients and physicians, during the 67th Annual Meeting of American Academy of Neurology (AAN) that will take place in Washington, DC between the 18th and the 25th of April, 2015. The data will…

Amarantus BioScience Holdings, Inc. (Amarantus) is a San Francisco based, development-stage, publicly-traded biotechnology company focused on discovering and developing first-in-class treatments and diagnostics in neurology for diseases associated with the dysfunction of a wide range of biological pathways, including protein misfolding, cell cycle dysregulation, neurodegeneration and apoptosis (Programmed Cell…

Biogen plans to present new clinical data at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C., April 18 – 25, 2015, including numerous presentations focusing on multiple sclerosis.  In a company press release, Biogen stated “At AAN, we will feature new scientific data, including research highlighting the…

MedDay recently announced in a news release that it is preparing to release the design and results of its clinical trial to assess the safety and efficacy of MD1003 in primary and secondary progressive multiple sclerosis (MS) treatment. Data on the Phase III clinical trial (MS-SPI) will be presented…

A stem cell therapy being administered to treat multiple sclerosis (MS) outside the United States was recently touted by an MS patient who traveled to Mexico to receive the therapy, revealing significant improvements in her quality of life. Debbie Bertrand, an MS patient who was diagnosed in 2001, is sharing her…

The National Multiple Sclerosis Society has announced it will grant $28 million to 84 new research projects and training awards focused on multiple sclerosis (MS). The new financial support is included in the society’s comprehensive research strategy, which was designed to not only end MS, but also restore patients’…

A recent study suggests that in the future multiple sclerosis patients could benefit from treatments intended to boost their brain function. The study was published in Nature Neuroscience and received funding from The Wellcome Trust, the Lister Research Prize and the Biotechnology and Biological Sciences Research Council. According to researchers, patients…

MedDay, a Paris, France based biotechnology company specializing in treatment of neurological disorders, has released more information regarding the design of its (MS-SPI) clinical trial that is investigating the efficacy and safety of the investigational medicine MD1003 in treatment of primary and secondary progressive multiple sclerosis (MS). Progressive…

The National Multiple Sclerosis (MS) Society recently released a recent paper on wellness titled “Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn?“ The paper focuses on how wellness can be achieved by…

The Foundation of the Consortium of Multiple Sclerosis Centers (FCMSC) is launching a new mentorship program dedicated to medical residents pursuing a neurology fellowship to accelerate and support their work in treating multiple sclerosis (MS). The initiative was launched at the beginning of the year and seeks to provide information on career…

A recent study published in PLOS ONE provides new insights into the relationship between the immune system and neurodegeneration and clinical disability in multiple sclerosis (MS). A team of researchers led by Dr. Shahin Aeinehband from the Neuroimmunology Unit at the Karolinska Institutet in Sweden looked at the association between…

What do multiple sclerosis and gout have in common? Uric acid. Uric acid, a byproduct of purine metabolism, causes crystal accumulation in joints (usually in the foot) and subsequent pain. Uric acid has also been shown to protect neurons via antioxidant activity. Since high levels of uric acid that…

Vaccinex, Inc. recently announced positive results for a multi center, randomized, double-blinded, placebo-controlled phase 1 clinical trial that evaluated single ascending-dose tolerability and safety in an experimental treatment for Multiple Sclerosis (MS) adult patients. The researchers enrolled 50 MS patients in one of five study groups (1, 3, 6, 10, and 20…

Can exercise help brain function in people with multiple sclerosis (MS)? A new study suggests that it is possible. The report appeared in the Journal of Clinical and Experimental Neuropsychology. Led by Robert Motl in the Department of Kinesiology and Community Health at the University of Illinois at…

Researchers at the IRCCS Centro Neurolesi “Bonino-Pulejo” and the University of Messina in Italy have performed a review on the immunomodulatory activity reported for statins in the treatment of multiple sclerosis (MS) and on clinical trial results. The study was published in the journal Pharmacological…

MS Research Australia has awarded a $150,000 grant to support a project being conducted at Murdoch University aimed at expanding scientific knowledge on the correlation between multiple sclerosis (MS) and Epstein-Barr virus infection. The research grant was awarded to David Nolan, an adjunct associate professor at the Institute of Immunology and Infectious Diseases (IIID),…

A major trial to investigate different ways to deal with attention and memory problems in multiple sclerosis (MS) patients will take place at Nottingham in the United Kingdom. The Cognitive Rehabilitation for Attention and Memory in people with Multiple Sclerosis (CRAMMS) study will focus on these MS related symptoms…

The Austrian Centre of Industrial Biotechnology (acib) developed a new purification method for pharmaceutical produced antibodies that promises to effectively decrease the high prices of these drugs in the market. Therapeutic antibodies revolutionized how doctors treat diseases affecting a large number of individuals, such as cancer and autoimmune…

Scientists are developing new tools to understand multiple sclerosis pathogenesis and monitor the benefits of treatments. One of these tools is diffusion tensor imaging (DTI), a novel technique that describes the microstructural organization of white matter tracts in the brain. Although DTI has greater pathological specificity than magnetic resonance imaging…

New research from Italy and Spain demonstrated that intense immunosuppression followed by autologous hematopoietic stem cell transplantation (AHSCT) was better than the medication mitoxantrone in treating severe cases of multiple sclerosis. The study appeared in the February 11, 2015, online issue of Neurology.  MS is characterized by an immune system attack on the…

The online community for neurologists Neurology Times will feature special coverage focused on multiple sclerosis (MS) in celebration of MS Awareness Month, which is currently taking place in March. The online platform was designed to provide healthcare professionals with informational resources about several hard…

Researchers at the University of Copenhagen and Rigshospitalet in Denmark have for the first time developed an accurate method to measure apolipoprotein M (apoM), a protein that is involved in several diseases like diabetes but also arteriosclerosis and sclerosis, disorders characterized by the stiffening of structures usually by…